Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $94000.0.

  • Utah Medical Products' Share-based Compensation rose 7735.85% to $94000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $334000.0, marking a year-over-year increase of 3046.88%. This contributed to the annual value of $256000.0 for FY2024, which is 1377.78% up from last year.
  • Per Utah Medical Products' latest filing, its Share-based Compensation stood at $94000.0 for Q3 2025, which was up 7735.85% from $86000.0 recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Share-based Compensation registered a high of $94000.0 during Q3 2025, and its lowest value of $38000.0 during Q3 2022.
  • For the 5-year period, Utah Medical Products' Share-based Compensation averaged around $57473.7, with its median value being $52000.0 (2024).
  • Within the past 5 years, the most significant YoY rise in Utah Medical Products' Share-based Compensation was 7826.09% (2021), while the steepest drop was 1632.65% (2021).
  • Utah Medical Products' Share-based Compensation (Quarter) stood at $43000.0 in 2021, then surged by 44.19% to $62000.0 in 2022, then rose by 16.13% to $72000.0 in 2023, then changed by 0.0% to $72000.0 in 2024, then skyrocketed by 30.56% to $94000.0 in 2025.
  • Its last three reported values are $94000.0 in Q3 2025, $86000.0 for Q2 2025, and $82000.0 during Q1 2025.